{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:20:51Z","timestamp":1791807651160,"version":"4.3.4"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.metabol.2021.154844","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T01:06:28Z","timestamp":1627779988000},"page":"154844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4442-7180","authenticated-orcid":false,"given":"Margaux","family":"Nawrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-6724","authenticated-orcid":false,"given":"Simon","family":"Peschard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-4757","authenticated-orcid":false,"given":"Sophie","family":"Lestavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-1503","authenticated-orcid":false,"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13300-020-00963-2","article-title":"Risk prediction of the diabetes missing million: identifying individuals at high risk of diabetes and related complications","volume":"12","author":"Evans","year":"2021","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","article-title":"Resolving the paradox of hepatic insulin resistance","volume":"7","author":"Santoleri","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154844_bb0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and mechanisms of nonalcoholic fatty liver disease","volume":"78","author":"Haas","year":"2016","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0025","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0035","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0050","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep4.1446","article-title":"Multiparametric magnetic resonance elastography improves the detection of NASH regression following bariatric surgery","volume":"4","author":"Allen","year":"2020","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0060","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology."},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0070","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0075","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI46045","article-title":"PKC\u03b4 regulates hepatic insulin sensitivity and hepatosteatosis in mice and humans","volume":"121","author":"Bezy","year":"2011","journal-title":"J Clin Invest"},{"issue":"7503","key":"10.1016\/j.metabol.2021.154844_bb0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0085","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1172\/JCI43378","article-title":"Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice","volume":"121","author":"Holland","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0095","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1172\/JCI57144","article-title":"Ceramides as modulators of cellular and whole-body metabolism","volume":"121","author":"Bikman","year":"2011","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2011.10.005","article-title":"Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans","volume":"56","author":"Pihlajam\u00e4ki","year":"2012","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0105","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41575-018-0065-y","article-title":"Apoptosis and necroptosis in the liver: a matter of life and death","volume":"15","author":"Schwabe","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0110","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","article-title":"Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease","volume":"371","author":"Shulman","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s42255-019-0076-1","article-title":"Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution","volume":"1","author":"Haas","year":"2019","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0120","doi-asserted-by":"crossref","first-page":"G211","DOI":"10.1152\/ajpgi.00040.2019","article-title":"CD8+ T cells regulate liver injury in obesity-related nonalcoholic fatty liver disease","volume":"318","author":"Breuer","year":"2020","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.metabol.2021.154844_bb0125","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"24","author":"Dudek","year":"2021","journal-title":"Nature."},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/hep4.1041","article-title":"Hepatic natural killer T-cell and CD8+ T-cell signatures in mice with nonalcoholic steatohepatitis","volume":"1","author":"Bhattacharjee","year":"2017","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0135","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/gutjnl-2015-310752","article-title":"Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury","volume":"66","author":"Arriazu","year":"2017","journal-title":"Gut."},{"issue":"31","key":"10.1016\/j.metabol.2021.154844_bb0140","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"Petersen","year":"2007","journal-title":"PNAS."},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/liv.14719","article-title":"Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"41","author":"Hsieh","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0150","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jhep.2021.02.037","article-title":"Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity","volume":"75","author":"Nachit","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0155","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.diabet.2019.10.004","article-title":"Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes","volume":"46","author":"Seo","year":"2020","journal-title":"Diabetes Metab"},{"issue":"14","key":"10.1016\/j.metabol.2021.154844_bb0160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0170","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","article-title":"Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaneurol.2017.3229","article-title":"Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the Framingham Study","volume":"75","author":"Weinstein","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.metabol.2021.154844_bb0180","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/liv.14161","article-title":"Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: the Framingham study","volume":"39","author":"Weinstein","year":"2019","journal-title":"Liver Int"},{"issue":"116","key":"10.1016\/j.metabol.2021.154844_bb0185","article-title":"Role of the gut in diabetic Dyslipidemia","volume":"11","author":"Stahel","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0190","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/ATVBAHA.113.302993","article-title":"Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects","volume":"34","author":"Veilleux","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0195","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/ATVBAHA.111.242073","article-title":"Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes","volume":"32","author":"Nogueira","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154844_bb0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.metabol.2017.04.004","article-title":"High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study","volume":"72","author":"Nass","year":"2017","journal-title":"Metabolism."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0210","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12182","article-title":"The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system","volume":"260","author":"Pelaseyed","year":"2014","journal-title":"Immunol Rev"},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0220","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nri2653","article-title":"Intestinal mucosal barrier function in health and disease","volume":"9","author":"Turner","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0225","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/gutjnl-2019-318427","article-title":"Leaky gut: mechanisms, measurement and clinical implications in humans","volume":"68","author":"Camilleri","year":"2019","journal-title":"Gut."},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0230","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154844_bb0235","first-page":"9(8)","article-title":"The intestinal barrier and current techniques for the assessment of gut permeability","volume":"17","author":"Schoultz","year":"2020","journal-title":"Cells."},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0240","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1007\/s00125-006-0465-3","article-title":"Increased intestinal permeability precedes clinical onset of type 1 diabetes","volume":"49","author":"Bosi","year":"2006","journal-title":"Diabetologia."},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0245","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0250","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology."},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0255","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"issue":"45","key":"10.1016\/j.metabol.2021.154844_bb0260","doi-asserted-by":"crossref","first-page":"17107","DOI":"10.3748\/wjg.v20.i45.17107","article-title":"Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease","volume":"20","author":"Pacifico","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0265","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes."},{"issue":"7610","key":"10.1016\/j.metabol.2021.154844_bb0270","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature18846","article-title":"Diet-microbiota interactions as moderators of human metabolism","volume":"535","author":"Sonnenburg","year":"2016","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0275","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41598-019-56743-x","article-title":"The nuclear receptor FXR inhibits glucagon-like peptide-1 secretion in response to microbiota-derived short-chain fatty acids","volume":"10","author":"Ducastel","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0280","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ni.3400","article-title":"Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease","volume":"17","author":"Mathewson","year":"2016","journal-title":"Nat Immunol"},{"issue":"44","key":"10.1016\/j.metabol.2021.154844_bb0285","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1073\/pnas.0407076101","article-title":"The gut microbiota as an environmental factor that regulates fat storage","volume":"101","author":"B\u00e4ckhed","year":"2004","journal-title":"PNAS."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0290","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","article-title":"Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism","volume":"24","author":"Wahlstr\u00f6m","year":"2016","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0295","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease","volume":"68","author":"Chu","year":"2019","journal-title":"Gut."},{"issue":"7418","key":"10.1016\/j.metabol.2021.154844_bb0300","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature11450","article-title":"A metagenome-wide association study of gut microbiota in type 2 diabetes","volume":"490","author":"Qin","year":"2012","journal-title":"Nature."},{"issue":"7452","key":"10.1016\/j.metabol.2021.154844_bb0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature12198","article-title":"Gut metagenome in European women with normal, impaired and diabetic glucose control","volume":"498","author":"Karlsson","year":"2013","journal-title":"Nature."},{"issue":"7402","key":"10.1016\/j.metabol.2021.154844_bb0310","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome","volume":"486","author":"Human Microbiome Project Consortium","year":"2012","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"7464","key":"10.1016\/j.metabol.2021.154844_bb0325","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature12506","article-title":"Richness of human gut microbiome correlates with metabolic markers","volume":"500","author":"Le Chatelier","year":"2013","journal-title":"Nature."},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/nu9111220","article-title":"Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis","volume":"9","author":"Chiu","year":"2017","journal-title":"Nutrients."},{"key":"10.1016\/j.metabol.2021.154844_bb0335","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fmicb.2017.01765","article-title":"Next-generation beneficial microbes: the case of Akkermansia muciniphila","volume":"8","author":"Cani","year":"2017","journal-title":"Front Microbiol"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0340","doi-asserted-by":"crossref","first-page":"e03004","DOI":"10.1128\/AEM.03004-19","article-title":"Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis","volume":"86","author":"Kim","year":"2020","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0345","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0350","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/hep.28829","article-title":"Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis","volume":"64","author":"Lelouvier","year":"2016","journal-title":"Hepatology."},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0355","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2337\/db07-1403","article-title":"Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet\u2013induced obesity and diabetes in mice","volume":"57","author":"Cani","year":"2008","journal-title":"Diabetes."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0360","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hep.31056","article-title":"Increased liver localization of lipopolysaccharides in human and experimental NAFLD","volume":"72","author":"Carpino","year":"2020","journal-title":"Hepatology."},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcmgh.2015.04.003","article-title":"The gut microbiota and liver disease","volume":"1","author":"Llorente","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154844_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jnutbio.2015.08.012","article-title":"Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice","volume":"27","author":"Chaudhry","year":"2016","journal-title":"J Nutr Biochem"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0375","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0380","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/toxsci\/kfh126","article-title":"Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes","volume":"79","author":"Raucy","year":"2004","journal-title":"Toxicol Sci"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0385","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154844_bb0390","doi-asserted-by":"crossref","first-page":"154712","DOI":"10.1016\/j.metabol.2021.154712","article-title":"Role of the gut microbiota in type 2 diabetes and related diseases","volume":"117","author":"Yang","year":"2021","journal-title":"Metabolism."},{"issue":"7480","key":"10.1016\/j.metabol.2021.154844_bb0395","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature12721","article-title":"Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells","volume":"504","author":"Furusawa","year":"2013","journal-title":"Nature."},{"issue":"7480","key":"10.1016\/j.metabol.2021.154844_bb0400","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0405","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3748\/wjg.v23.i1.60","article-title":"Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier","volume":"23","author":"Zhou","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0410","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/intimm\/dxz078","article-title":"Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon","volume":"32","author":"Isobe","year":"2020","journal-title":"Int Immunol"},{"issue":"7341","key":"10.1016\/j.metabol.2021.154844_bb0415","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0420","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","article-title":"From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites","volume":"165","author":"Koh","year":"2016","journal-title":"Cell."},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0425","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2018.09.055","article-title":"Microbially produced imidazole propionate impairs insulin signaling through mTORC1","volume":"175","author":"Koh","year":"2018","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0430","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0435","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MOL.0000000000000597","article-title":"Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?","volume":"30","author":"Ch\u00e1vez-Talavera","year":"2019","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0440","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1210\/jc.2016-1607","article-title":"Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes","volume":"101","author":"Sonne","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0445","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0450","doi-asserted-by":"crossref","first-page":"100222","DOI":"10.1016\/j.jhepr.2020.100222","article-title":"NASH-related increases in plasma bile acid levels depend on insulin resistance","volume":"3","author":"Grzych","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0460","doi-asserted-by":"crossref","first-page":"G412","DOI":"10.1152\/ajpgi.00300.2018","article-title":"Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice","volume":"316","author":"Finn","year":"2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0465","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor \u03ba light-chain enhancer of activated B cells (NF-\u03baB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology."},{"issue":"10","key":"10.1016\/j.metabol.2021.154844_bb0470","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Alvarez-Sola","year":"2017","journal-title":"Gut."},{"issue":"10","key":"10.1016\/j.metabol.2021.154844_bb0475","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.metabol.2021.154844_bb0480","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs."},{"issue":"9972","key":"10.1016\/j.metabol.2021.154844_bb0485","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0490","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J Med Chem"},{"issue":"24","key":"10.1016\/j.metabol.2021.154844_bb0495","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic Steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0500","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","article-title":"Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity","volume":"60","author":"Prawitt","year":"2011","journal-title":"Diabetes."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms8629","article-title":"Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells","volume":"6","author":"Trabelsi","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0510","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.metabol.2021.154844_bb0520","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0525","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell."},{"key":"10.1016\/j.metabol.2021.154844_bb0530","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3389\/fimmu.2020.00587","article-title":"The Paneth cell: the curator and defender of the immature small intestine","volume":"11","author":"Lueschow","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0535","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12400","article-title":"Peyer\u2019s patches: organizing B-cell responses at the intestinal frontier","volume":"271","author":"Reboldi","year":"2016","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0540","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.immuni.2017.06.013","article-title":"Human secretory igm emerges from plasma cells clonally related to gut memory B cells and targets highly diverse commensals","volume":"47","author":"Magri","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0545","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-019-11370-y","article-title":"Gut-associated IgA+ immune cells regulate obesity-related insulin resistance","volume":"10","author":"Luck","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0550","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.it.2017.11.003","article-title":"Intestinal intraepithelial lymphocytes: sentinels of the mucosal barrier","volume":"39","author":"Olivares-Villag\u00f3mez","year":"2018","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0555","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.immuni.2011.01.016","article-title":"Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria","volume":"34","author":"Hadis","year":"2011","journal-title":"Immunity."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0560","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.07.048","article-title":"Self-maintaining gut macrophages are essential for intestinal homeostasis","volume":"175","author":"De Schepper","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0565","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0570","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.immuni.2015.12.021","article-title":"What makes MAITs wait?","volume":"44","author":"Exley","year":"2016","journal-title":"Immunity."},{"key":"10.1016\/j.metabol.2021.154844_bb0575","doi-asserted-by":"crossref","first-page":"571731","DOI":"10.3389\/fimmu.2020.571731","article-title":"Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes","volume":"11","author":"Scheithauer","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0580","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI88879","article-title":"Immunologic impact of the intestine in metabolic disease","volume":"127","author":"Winer","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0585","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cmet.2016.07.009","article-title":"Colonic pro-inflammatory macrophages cause insulin resistance in an intestinal Ccl2\/Ccr2-dependent manner","volume":"24","author":"Kawano","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0590","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cmet.2015.05.020","article-title":"Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling","volume":"22","author":"Monteiro-Sepulveda","year":"2015","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0595","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0600","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0605","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2337\/dc17-2654","article-title":"Metabolic (bariatric and nonbariatric) surgery for type 2 diabetes: a personal perspective review","volume":"42","author":"Buchwald","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0610","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.soard.2017.09.527","article-title":"Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review","volume":"14","author":"Souto","year":"2018","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0615","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0620","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0625","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/SLA.0000000000003871","article-title":"Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis","volume":"272","author":"Wirth","year":"2020","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0630","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s11695-020-04622-0","article-title":"The impact of bariatric surgery on hepatic function and predictors of liver steatosis and fibrosis","volume":"30","author":"Borges-Canha","year":"2020","journal-title":"Obes Surg"},{"issue":"10126","key":"10.1016\/j.metabol.2021.154844_bb0635","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0640","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0645","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154844_bb0650","author":"NGM"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0655","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"10215","key":"10.1016\/j.metabol.2021.154844_bb0660","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0665","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","article-title":"INT-767 improves histopathological features in a diet-induced Ob\/Ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis","volume":"24","author":"Roth","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0670","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-17-0557","article-title":"INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function","volume":"238","author":"Comeglio","year":"2018","journal-title":"J Endocrinol"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0675","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatology Communications"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0680","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","article-title":"A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR","volume":"11","author":"Downes","year":"2003","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0685","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","article-title":"Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism","volume":"68","author":"Pathak","year":"2018","journal-title":"Hepatology."},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0690","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0695","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology."},{"issue":"10019","key":"10.1016\/j.metabol.2021.154844_bb0700","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0705","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2021.154844_bb0710","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0715","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0720","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia."},{"key":"10.1016\/j.metabol.2021.154844_bb0725","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"13","author":"Newsome","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0730","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"issue":"4","key":"10.1016\/j.metabol.2021.154844_bb0735","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.metabol.2021.154844_bb0740","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.metabol.2021.154844_bb0745","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0750","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.0605374104","article-title":"Mechanisms underlying the resistance to diet-induced obesity in germ-free mice","volume":"104","author":"B\u00e4ckhed","year":"2007","journal-title":"PNAS."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0755","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13073-016-0297-9","article-title":"Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet","volume":"8","author":"Mahana","year":"2016","journal-title":"Genome Med"},{"issue":"10","key":"10.1016\/j.metabol.2021.154844_bb0760","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154844_bb0765","first-page":"12(4)","article-title":"Randomised double-blind placebo-controlled trial of inulin with metronidazole in non-alcoholic fatty liver disease (NAFLD)","volume":"27","author":"Chong","year":"2020","journal-title":"Nutrients."},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0770","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154844_bb0775","doi-asserted-by":"crossref","first-page":"558525","DOI":"10.3389\/fphar.2020.558525","article-title":"Inulin exerts beneficial effects on non-alcoholic fatty liver disease via modulating gut microbiome and suppressing the lipopolysaccharide-Toll-like receptor 4-M\u03c8-nuclear factor-\u03baB-nod-like receptor protein 3 pathway via gut-liver Axis in mice","volume":"11","author":"Bao","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.metabol.2021.154844_bb0780","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"issue":"8","key":"10.1016\/j.metabol.2021.154844_bb0785","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154844_bb0790","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/JOE-17-0592","article-title":"Lactobacillus acidophilus NS1 attenuates diet-induced obesity and fatty liver","volume":"237","author":"Park","year":"2018","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0795","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.metabol.2021.154844_bb0800","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.metabol.2021.154844_bb0805","first-page":"12(11)","article-title":"Prebiotic xylo-oligosaccharides ameliorate high-fat-diet-induced hepatic steatosis in rats","volume":"22","author":"Lensu","year":"2020","journal-title":"Nutrients."},{"issue":"1","key":"10.1016\/j.metabol.2021.154844_bb0810","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prev Med"},{"issue":"3","key":"10.1016\/j.metabol.2021.154844_bb0815","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.metabol.2021.154844_bb0820","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.metabol.2021.154844_bb0825","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952100144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952100144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:28:14Z","timestamp":1758428894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952100144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":165,"alternative-id":["S002604952100144X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154844","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154844"}}